CClinicalTrials.gg
CompletedNCT03954717Updated Aug 2, 2023

Pilot Study Evaluating Functional and Wellness Outcomes of the Shepherd CAN DO MS Program

An observational study in Multiple Sclerosis, sponsored by Shepherd Center, Atlanta GA. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-02.

Sponsored by Shepherd Center, Atlanta GA · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
111
Ages
18 Years and older
Sex
All
01

Study summary

The study evaluates the efficacy of the CAN DO Program for improving health, wellness, and quality of life in people with MS, and compares outcomes between people with MS who participate in the CAN DO Program to a control group of people with MS who do not participate in the CAN DO Program. The study also evaluates the impact of the CAN DO Program on support partners.

Read the detailed description

Can Do MS Programs offer evidence-based, comprehensive, and personalized educational and experiential opportunities aimed at empowering and enabling a person with MS to live a healthy life beyond their MS. The signature program of Can Do MS is the four-day CAN DO® Program (CAN DO). Preliminary outcomes suggest that participation in CAN DO leads to significant improvements in self-efficacy and various aspects of health status.1 The majority of 129 participants who participated in one of the three CAN DO Programs showed improvements in self-efficacy at one month (n=98), 3 months (n=84), and 6 months after the program (n=82; all p\<0.001). Participants also showed significant improvements to varying degrees in subscales of the SF-36, including Physical Functioning (p=0.01), Role Physical, General Health, Vitality and Mental Health. These improvements were maintained to varying extents at one and 3 months post-program.

These important outcomes have not yet been compared to those in people with MS who receive traditional care but do not participate in this comprehensive educational opportunity. Furthermore, the impact on physical activity, participation, and quality of life has not been measured or compared to those who do not participate in CAN DO. Finally, recognizing the tremendous burden that can be placed on the support partner living and supporting a person with MS, education for support partners is another critical element of CAN DO. However, the impact on the support partner of empowering an individual with MS to adopt healthy behaviors also has not been assessed.

This project will allow Shepherd Center and Can Do MS to gather long-term health, wellness, and quality of life outcomes in people with MS and their support partners, as well as pilot data evaluating this study design for future larger scale clinical trials. Demonstrating the efficacy of this program will provide evidence that will impact the lives of people with MS and their families, specifically, their ability to live healthy lives independent of their MS.

02

Conditions studied

  • Multiple Sclerosis

Browse trials for

03

In context

Multiple Sclerosis

3,460 studies on the registry are indexed under Multiple Sclerosis; 661 are open to participants now.

This study's enrollment of 111 is above the median of 100 across 1,016 observational studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Shepherd Center, Atlanta GA is the lead sponsor of 20 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Twenty-four people with MS and their support partners participating in the May 2019 Shepherd CAN DO Program, and two control groups (CG) matched to program participants for age, sex, type of MS, and level of disability:

CG-S = 24 current patients of the MS Institute at Shepherd and their support partners willing to complete surveys via an electronic platform.

CG-iCMS = 24 iConquerMS members and their support partners willing to complete the same outcomes. These participants can be from anywhere in the US, but cannot participate in any of the Can Do MS programs at any time prior to the study.

Inclusion criteria

  • CAN DO Program group: have MS and participated in the May 2019 Shepherd CAN DO Program
  • CG-iCMS: Have MS

Exclusion criteria

Exclusion Criteria:

  • CAN DO Program group: Active members of the Shepherd Center MS Wellness Program, or who have previously been a participant in any CAN DO MS Programs.
  • CG-iCMS: Cannot participate in any of the CAN DO MS Programs at any time prior to the study
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
111 participants (actual)
Patient registry
No

Groups and cohorts

  • Participants in the Shepherd CAN DO Program

    People with MS enrolled into the Shepherd CAN DO Program.

    Behavioral: Shepherd CAN DO Program

  • Control Group-Shepherd (CG-S)

    People with MS who are current patients of the MS Institute at the Shepherd Center.

  • Control Group-iConquerMS (CG-iCMS)

    iConquerMS members

  • Support partners of CAN DO

    Support partners of the participants in the Shepherd CAN DO Program group

    Behavioral: Shepherd CAN DO Program

  • CG-S support partners

    Support partners of the people with MS in the CG-S group.

  • CG-iCMS

    Support partners of the people with MS in the CG-iCMS group

Interventions

  • BehavioralShepherd CAN DO Program

    CAN DO Shepherd is a four-day participatory program held at the Shepherd Center, in Atlanta, Georgia or people with MS. The four-day program comprises evidence-based, comprehensive, and personalized educational and experiential opportunities aimed at empowering and enabling a person with MS to live a health life beyond their MS.

06

What researchers measure

Primary outcomes

  1. Change in self-efficacy for symptom management at 6 months

    The extent to which participants demonstrate increased self-efficacy (the confidence in one's belief to undertake a task) to manage symptoms measured by the Multiple Sclerosis Self-Management Scale Revised (MSSM-R) Constructs measured: * Healthcare provider relationship \& communication * Treatment adherence/barriers * Social/family support * MS knowledge \& information * Health maintenance behavior 24 items, with score 1 (disagree completely) to 5 (agree completely) For some 1 is a positive outcome and for others 5 is a positive outcome; the scores and transformed and scaled for each participant

    Time frame: 6 months

  2. Change in self-efficacy for symptom management at 12 months

    The extent to which participants demonstrate increased self-efficacy (the confidence in one's belief to undertake a task) to manage symptoms measured by the Multiple Sclerosis Self-Management Scale Revised (MSSM-R) Constructs measured: * Healthcare provider relationship \& communication * Treatment adherence/barriers * Social/family support * MS knowledge \& information * Health maintenance behavior 24 items, with score 1 (disagree completely) to 5 (agree completely) For some 1 is a positive outcome and for others 5 is a positive outcome; the scores and transformed and scaled for each participant

    Time frame: 12 months

  3. Change in self-efficacy for symptom management at 24 months

    The extent to which participants demonstrate increased self-efficacy (the confidence in one's belief to undertake a task) to manage symptoms measured by the Multiple Sclerosis Self-Management Scale Revised (MSSM-R) Constructs measured: * Healthcare provider relationship \& communication * Treatment adherence/barriers * Social/family support * MS knowledge \& information * Health maintenance behavior 24 items, with score 1 (disagree completely) to 5 (agree completely) For some 1 is a positive outcome and for others 5 is a positive outcome; the scores and transformed and scaled for each participant

    Time frame: 24 months

  4. Change in self-efficacy for quality of life at 6 months

    The extent to which self-efficacy to undertake tasks related to quality of life increases over time as measured by the Exercise Self-Efficacy Scale (ESES) The Exercise Self-Efficacy Scale assesses an individual's beliefs in their ability to continue exercising on a three time per week basis at moderate intensities for 40+ minutes per session in the future. For each item, participants indicate their confidence to execute the behavior on a 100-point percentage scale comprised of 10-point increments, ranging from 0% (not at all confident) to 100% (highly confident). Total strength for each measure of self-efficacy is then calculated by summing the confidence ratings and dividing by the total number of items in the scale, resulting in a maximum possible efficacy score of 100.

    Time frame: 6 months

  5. Change in self-efficacy for quality of life at 12 months

    The extent to which self-efficacy to undertake tasks related to quality of life increases over time as measured by the Exercise Self-Efficacy Scale (ESES) The Exercise Self-Efficacy Scale assesses an individual's beliefs in their ability to continue exercising on a three time per week basis at moderate intensities for 40+ minutes per session in the future. For each item, participants indicate their confidence to execute the behavior on a 100-point percentage scale comprised of 10-point increments, ranging from 0% (not at all confident) to 100% (highly confident). Total strength for each measure of self-efficacy is then calculated by summing the confidence ratings and dividing by the total number of items in the scale, resulting in a maximum possible efficacy score of 100.

    Time frame: 12 months

  6. Change in self-efficacy for quality of life at 24 months

    The extent to which self-efficacy to undertake tasks related to quality of life increases over time as measured by the Exercise Self-Efficacy Scale (ESES) The Exercise Self-Efficacy Scale assesses an individual's beliefs in their ability to continue exercising on a three time per week basis at moderate intensities for 40+ minutes per session in the future. For each item, participants indicate their confidence to execute the behavior on a 100-point percentage scale comprised of 10-point increments, ranging from 0% (not at all confident) to 100% (highly confident). Total strength for each measure of self-efficacy is then calculated by summing the confidence ratings and dividing by the total number of items in the scale, resulting in a maximum possible efficacy score of 100.

    Time frame: 24 months

Secondary outcomes

  1. Change in caregiver perception of burden at 6 months

    The extent to which caregivers of participants demonstrate decreased perception of caregiver burden as measured by the Zarit Burden Interview (ZBI) The ZBI consists of 22 items rated on a 5-point Likert scale that ranges from 0 (never) to 4 (nearly always) with the sum of scores ranging between 0-88. 9. Higher scores indicate greater burden. A score of 17 or more was considered high burden.

    Time frame: 6 months

  2. Change in caregiver perception of burden at 12 months

    The extent to which caregivers of participants demonstrate decreased perception of caregiver burden as measured by the Zarit Burden Interview (ZBI) The ZBI consists of 22 items rated on a 5-point Likert scale that ranges from 0 (never) to 4 (nearly always) with the sum of scores ranging between 0-88. 9. Higher scores indicate greater burden. A score of 17 or more was considered high burden.

    Time frame: 12 months

  3. Change in caregiver perception of burden at 24 months

    The extent to which caregivers of participants demonstrate decreased perception of caregiver burden as measured by the Zarit Burden Interview (ZBI) The ZBI consists of 22 items rated on a 5-point Likert scale that ranges from 0 (never) to 4 (nearly always) with the sum of scores ranging between 0-88. 9. Higher scores indicate greater burden. A score of 17 or more was considered high burden.

    Time frame: 24 months

07

Study locations

1 site
  • Shepherd Center
    Atlanta, Georgia 30303, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03954717
Lead sponsor
Shepherd Center, Atlanta GA
Collaborators
Genzyme, a Sanofi Company, Can Do Multiple Sclerosis
Responsible party
Deborah Backus (Director of Multiple Sclerosis Research, Shepherd Center, Atlanta GA) — Principal investigator
First posted
May 17, 2019
Start date
May 14, 2019
Primary completion
Mar 11, 2022
Completion
Mar 11, 2022
Last update
Aug 2, 2023

Study contacts

Deborah Backus, PhD, PT
principal investigator · Shepherd Center, Atlanta GA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion